(Q41522164)

2 October 2017

1 reference

title

Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance (English)

1 reference

2 October 2017

1 reference

Nicas TI

1

1 reference

PubMed ID

9211645

2 October 2017

Zeckel ML

series ordinal

2

1 reference

PubMed ID

9211645

2 October 2017

Braun DK

series ordinal

3

1 reference

2 October 2017

1 June 1997

1 reference

2 October 2017

Trends in Microbiology

1 reference

2 October 2017

5

1 reference

2 October 2017

240-249

1 reference

2 October 2017

6

1 reference

Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

2 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

What can we do about vancomycin-resistant enterococci?

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Peritonitis due to vancomycin-resistant Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Emergence of vancomycin resistance in coagulase-negative staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

vanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium (Corynebacterium) haemolyticum.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

First report of vancomycin-resistant Streptococcus mitis bacteremia in a leukemic patient after prophylaxis with quinolones and during treatment with vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Recommendations for preventing the spread of vancomycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

van A-Mediated vancomycin-resistant Enterococcus spp. in sewage

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Glycopeptide resistance in enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Genetics and mechanisms of glycopeptide resistance in enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Mechanisms of glycopeptide resistance in enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Current perspectives on glycopeptide resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Phenotypic and genotypic heterogeneity of glycopeptide resistance determinants in gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Structure-activity relationships of vancomycin-type glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Structural modifications of glycopeptide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

The glycopeptide story--how to kill the deadly 'superbugs'.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Quinupristin-dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Comparative in-vitro activity of SCH 27899, a novel everninomicin, and vancomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

In-vitro activity of two glycylcyclines against enterococci resistant to other agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H+ antiporter

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Nosocomial acquisition of Clostridium difficile infection

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2897%2901051-2

7 January 2021

10.1016/S0966-842X(97)01051-2

Identifiers

DOI

1 reference

2 October 2017

1 reference

PubMed ID

9211645